(MENAFN- Ameliorate Digital Consultancy) The single photon emission computed tomography (spect) market is predicted to grow at a notable CAGR of 6.8% from 2022 to 2026, according to Fact.MR's most recent industry report.

During the projected period (2022-2026), it is anticipated that the cardiology application segment would grow significantly. Rapid segmental expansion can be attributed to factors including increased cardiovascular disorder prevalence, rising use of cardiovascular OCT imaging tools, and rising public knowledge of heart illness diagnosis.

High-quality findings from SPECT systems are produced as a result of precise measurement and operation. But current advancements in digital technology and medical imaging methods using a range of modalities are opening the door to early disease detection and treatment.

For Critical Insights on this Market, Request for More Info at:

To improve the diagnostic accuracy of the equipment, there is an increasing tendency towards organ-specific systems, which is anticipated to drive market expansion over the coming years. The simultaneous use of many modalities that can provide information about the physical, functional, and molecular changes of several diseases is expected to drive market growth going forward.

Additionally, the growing need for comprehensive imaging techniques by academic institutions and universities to give advanced training is anticipated to have a substantial impact on market growth during the forecast period. The development of diagnostic tools has also been expedited by advancements in digital and communications technology. New imaging techniques that reveal additional anatomical details are available in a majority of diagnostic laboratories and hospitals.

Key T akeaways from Market Study

• Global single photon emission computed tomography market to reach valuation of US$ 2.6 billion by 2026.
• Market in Germany set to expand at CAGR of 5.5% over forecast period.
• Market in Japan expected to rise at CAGR of 5.7% from 2022 to 2026.
• Demand for hybrid systems projected to rise at CAGR of 7% through 2026.

“Early diagnostic methods, expanding range of therapeutic trials, rise in geriatric population and consequent rise in the prevalence of chronic disorders, technological advancements in medical diagnostics, and increase in investments, funding, and subsidies by public-private organizations are factors supporting market growth,” says a Fact.MR analyst

Rising Need for Accurate System Calibration & Operation for Better-quality Outcomes Driving Market Value

Blood flow through arteries and veins in the brain and spine can be detected with a single photon emission computed tomography scan. Because single photon emission computed tomography systems are used to detect decreased blood flow to affected regions, they may offer more accurate results for brain injury.

A crucial diagnostic tool where anatomical details can discriminate between functional and metabolic data is the combination of X-ray computed tomography (CT) and single photon emission computed tomography, thanks to recent developments in medical imaging.

Single photon emission computed tomography systems can be helpful in the diagnosis of a variety of disorders, including tremors, attacks, and Alzheimer's disease. Using single photon emission computed tomography scanners, 2D and 3D pictures are generated. The demand for tomographic imaging techniques is being driven by a growing need for reliable system calibration and operation for better-quality results.

The market is growing because to improvements in single photon emission computed tomography technology as well as an increase in the prevalence of cancer and cardiovascular diseases globally.

Winning Strategy

Key companies in the SPECT market are investing in R&D initiatives for developments in CT and MRI technology to provide accurate anatomical information. To stand out in the market, major firms should concentrate more on the opportunities for growth in the rapidly expanding market segments.

For instance,

• • In 2021, Noria Therapeutics Inc. and PSMA Therapeutics Inc. entered into a contract with Bayer. Through this transaction, Bayer will gain unique access to a small molecule targeted at prostate-specific membrane antigen and a differentiated alpha radionuclide investigational drug based on actinium-225.

Get Customization on this Report for Specific Country:

Single Photon Emission Computed Tomography Industry Research Segmentation

• By Product :
  • Standalone
  • Hybrid
• By Radioisotope :
  • Tc-99m
  • Ra-223
  • Ga-67
  • I-123
  • Others
• By Application :
  • Cardiology
  • Oncology
  • Neurology
  • Others
• By End User :
  • Hospitals
  • Diagnostic Centers
  • Others
• By Region :
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email:

MENAFN09072023004660010643ID1106574893